ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
Health Technology

Takeda Pharmaceutical Co., Ltd.

Business Summary

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Financial Highlights

Mar 2023 JPYUSD
Gross Profit2,298.31B16,959.55M
Operating income658,291M4,857.61M
Income before tax383,720M2,831.51M
Net income317,017M2,339.30M
Diluted EPS201.931.49
Dividends Per Share1801.32
Total Assets13,957.75B104,874.52M
Total liabilities7,603.08B57,127.35M
Total equity6,354.12B47,743.04M
Operating cash flow877,217M6,473.09M
Currency in JPYCurrency in USD

Historical Data

 Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Revenue 2,097.22B 3,291.18B 3,197.81B 3,569.00B 4,027.47B
Gross Profit 1,275.55B 1,789.37B 1,798.37B 2,043.63B 2,298.31B
Operating income 218,686M 302,612M 447,610M 610,496M 658,291M
Income before tax 127,612M -60,754M 366,159M 317,938M 383,720M
Net income 135,192M 44,241M 376,005M 230,059M 317,017M
EBITDA 466,377M 886,261M 1,007.28B 1,193.64B 1,322.69B
Diluted EPS 139.82 28.24 238.95 145.86 201.93
Dividends Per Share 180 180 180 180 180
Total Assets 13,792.77B 12,821.09B 12,912.29B 13,178.01B 13,957.75B
Total liabilities 8,606.78B 8,093.60B 7,735.11B 7,494.49B 7,603.08B
Total equity 5,181.98B 4,723.48B 5,173.03B 5,683.01B 6,354.12B
Operating cash flow 302,609M 555,410M 905,073M 1,021.21B 877,217M
 Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Revenue 18,911.85M 30,270.54M 30,151.70M 31,760.44M 29,719.25M
Gross Profit 11,502.42M 16,457.72M 16,956.61M 18,186.20M 16,959.55M
Operating income 1,972.01M 2,783.25M 4,220.44M 5,432.77M 4,857.61M
Income before tax 1,150.74M -558.78M 3,452.46M 2,829.31M 2,831.51M
Net income 1,219.10M 406.90M 3,545.29M 2,047.28M 2,339.30M
EBITDA 4,205.58M 8,151.34M 9,497.50M 10,622.21M 9,760.29M
Diluted EPS 1.26 0.25 2.25 1.29 1.49
Dividends Per Share 1.62 1.65 1.69 1.60 1.32
Total Assets 124,612.85M 118,763.31M 116,853.33M 108,572.75M 104,874.52M
Total liabilities 77,759.25M 74,972.05M 70,001.05M 61,746.62M 57,127.35M
Total equity 46,817.41M 43,754.18M 46,814.81M 46,821.99M 47,743.04M
Operating cash flow 2,728.79M 5,108.35M 8,533.80M 9,087.77M 6,473.09M

Valuation Measures

Mar 2023
Operating margin16.34%
Profit margin7.87%


  • President, CEO & Director: Christophe Weber
  • Chief Financial Officer & Director: Constantine Saroukos
  • Director, President-Research & Development: Andrew S. Plump
  • Chief Medical & Scientific Officer: Michael E. Mendelsohn
  • Chief Data & Technology Officer: Gabriele Ricci


  • Nomura Asset Management Co., Ltd. (4.3%)
  • Sumitomo Mitsui Trust Asset Management Co., Ltd. (3.8%)
  • The Vanguard Group, Inc. (3.3%)
  • BlackRock Fund Advisors (2.0%)
  • Nikko Asset Management Co., Ltd. (2.0%)
  • Daiwa Asset Management Co. Ltd. (2.0%)
  • Nippon Life Insurance Co. (1.7%)
  • Capital International Ltd. (1.7%)
  • Norges Bank Investment Management (1.5%)
  • Capital Research & Management Co. (Global Investors) (1.4%)

Contact Details

Related Companies

  • Nimbus Lakshmi, Inc.
  • Takeda Digital Ventures
  • Takeda Pharmaceutical Employee Long Term Incentive Plan
  • Takeda Dunboyne Biologics Ltd.
  • Plasmaspendedienst GmbH
  • Takeda Belgium NV
  • Takeda Pharmaceutical Co. Ltd. /Non Core Assets/
  • Adaptate Biotherapeutics Ltd.
  • Takeda Re Insurance AG
  • Plasmapunkt Favoriten GmbH
  • Takeda Malaysia Sdn. Bhd.
  • Takeda Pharmaceutical Co. Ltd. /Latam Bus/
  • Takeda Oranienburg Real Estate GmbH & Co. KG
  • Pvp Biologics, Inc.
  • Maverick Therapeutics, Inc.
  • Gammadelta Therapeutics Ltd.
  • Takeda Pharmaceutical Director Incentive Plan
  • Takeda Pharmaceutical Employee Incentive Plan
  • Oy Leiras Takeda Pharmaceuticals AB
  • Takeda Architectural Design Consulting (Shanghai) Co. Ltd.
  • Takeda Pharma AB
  • Takeda Development Center Americas, Inc.
  • Takeda Ukraine LLC
  • Takeda Pharmaceuticals Taiwan Ltd.
  • Takeda SRL
  • Takeda Hellas SA
  • Takeda Christiaens SCA/CVA
  • Takeda Belgium SCA/CVA
  • Takeda Vaccines Pte Ltd.
  • Takeda Development Center Asia Pte Ltd.


  • AstraZeneca PLC
  • CSL Limited
  • Grifols, S.A. Class A
  • Amgen Inc.
  • Green Cross Corporation
  • Novo Nordisk A/S Class B
  • Protalix Biotherapeutics, Inc.
  • Galapagos NV
  • BioMarin Pharmaceutical Inc.
  • Amicus Therapeutics, Inc.
  • Pharming Group NV
  • ADMA Biologics, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Johnson & Johnson
  • Eisai Co., Ltd.
  • AbbVie, Inc.
  • Bristol-Myers Squibb Company
  • Organon & Co.
  • Merck & Co., Inc.
  • Roche Holding Ltd Dividend Right Cert.
  • Bayer AG
  • Swedish Orphan Biovitrum AB
  • Gilead Sciences, Inc.
  • Karyopharm Therapeutics, Inc.
  • ISU Abxis Co., Ltd.
  • JCR Pharmaceuticals Co., Ltd.
  • Supernus Pharmaceuticals, Inc.
  • Oncopeptides AB
Last Updated on 22 Sep, 2023

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more